A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Clinical trial NCT02655237 · COMPLETED
Trial details
- NCT number
- NCT02655237
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-05
- Primary completion
- 2017-05-17
- Enrollment
- 281
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.